MG2 is pleased to announce the appointment of Dr. Massimiliano Passerini as new Sales Director. Graduated in Chemistry, with a wide international experience, Passerini brings with him a strategic vision aimed at innovation and global development. His ten years of experience in the United States has given him a deep understanding of the industrial dynamics and needs of pharmaceutical multinationals.
What challenges does MG2 face and what strategies will you adopt?
"The analysis of market trends is crucial for an effective strategy, especially in a constantly changing environment. Today the market shows on one hand a consolidation of the pharmaceutical multinationals, increasingly focused on research and development, and on the other hand a strengthening of contract manufacturing and outsourcing. At the production level, there is also an increase in reshoring, due to public policies aimed at bringing back the production of strategic drugs. Coordination is a crucial aspect: all parties involved must operate in their individual market, but with a global perspective. It is crucial for all employees to comprehend the significance of their project in the context of interconnected, even distant markets. Each activity is part of an integrated global system. My goal is therefore to develop a global strategy, linked to the specificities of individual markets, but coordinated on a large scale, where each MG2 agent is part of a cohesive and synergistic team".
How do you see the future of the pharmaceutical market in the coming years, considering AI and IoT?
" New product niches are emerging in the market, such as monoclonal antibodies, oncology drugs, and inhalants. MG2 is facing significant technological challenges due to these high-value solutions. The objective is to serve as a reference in the packaging of capsules for these new drugs, which necessitate advanced technologies and above-average investment. The industry is moving away from generic drugs and looking more and more at bio-similars, the new frontier of pharmaceuticals.
The production and commercial strategies of MG2 are part of this framework where large factories have been gradually decreasing their production in favor of outsourcing, both for research and development phases and production. This scenario makes increasingly strategic tools such as big data, artificial intelligence (AI) and data mining, which allow to coordinate and optimize activities between the different parties involved".
With this appointment, MG2 strengthens its commitment to excellence and innovation by relying on the leadership of Passerini to consolidate the company's growth and successfully tackle future challenges in the global market.
www.mg2.it
